NZ719934A - Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors - Google Patents
Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectorsInfo
- Publication number
- NZ719934A NZ719934A NZ719934A NZ71993414A NZ719934A NZ 719934 A NZ719934 A NZ 719934A NZ 719934 A NZ719934 A NZ 719934A NZ 71993414 A NZ71993414 A NZ 71993414A NZ 719934 A NZ719934 A NZ 719934A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nucleic acids
- early
- rna transcripts
- heterologous
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ759538A NZ759538A (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005541 | 2013-11-28 | ||
| PCT/EP2014/075522 WO2015078856A1 (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ719934A true NZ719934A (en) | 2022-10-28 |
Family
ID=49680779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ719934A NZ719934A (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
| NZ759538A NZ759538A (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ759538A NZ759538A (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20160376596A1 (https=) |
| EP (2) | EP3971298A3 (https=) |
| JP (2) | JP6641276B2 (https=) |
| KR (1) | KR102504316B1 (https=) |
| CN (1) | CN105829537B (https=) |
| AU (3) | AU2014356546A1 (https=) |
| BR (1) | BR112016011866A2 (https=) |
| CY (1) | CY1124707T1 (https=) |
| DK (1) | DK3074517T3 (https=) |
| EA (1) | EA039037B1 (https=) |
| ES (1) | ES2895977T3 (https=) |
| HU (1) | HUE056105T2 (https=) |
| IL (1) | IL245509B (https=) |
| LT (1) | LT3074517T (https=) |
| MX (1) | MX377258B (https=) |
| MY (1) | MY188100A (https=) |
| NZ (2) | NZ719934A (https=) |
| PT (1) | PT3074517T (https=) |
| SI (1) | SI3074517T1 (https=) |
| UA (1) | UA127337C2 (https=) |
| WO (1) | WO2015078856A1 (https=) |
| ZA (1) | ZA201603187B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050790B (zh) * | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| KR20210031485A (ko) | 2018-07-13 | 2021-03-19 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | Tnf를 발현하는 점액종 바이러스로 암을 치료하는 방법 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| TW202122411A (zh) | 2019-09-02 | 2021-06-16 | 美國亞利桑那州立大學亞利桑那州評議委員會 | 以黏液瘤(myxoma)病毒治療癌症之新穎溶瘤病毒平臺 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP3957322A1 (en) * | 2020-08-19 | 2022-02-23 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Recombinant poxviridae vector expressing co-stimulatory molecules |
| CN117999090A (zh) * | 2021-05-13 | 2024-05-07 | 托马斯杰弗逊大学 | 鼠痘病毒用于癌症免疫治疗和疫苗的用途 |
| CN115043948B (zh) * | 2022-06-24 | 2024-05-28 | 青岛硕景生物科技有限公司 | 一种猴痘病毒特异性融合蛋白抗原及其制备方法和应用 |
| GB202407035D0 (en) * | 2024-05-17 | 2024-07-03 | Uncommon Bio Ltd | RNA constructs with immune blocking agents |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5519239A (en) * | 1978-07-28 | 1980-02-09 | Green Cross Corp:The | Interferon-producing attractant |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| DK1137792T3 (da) * | 1998-12-09 | 2007-09-10 | Us Gov Health & Human Serv | En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf |
| DE60038011T2 (de) * | 1999-04-08 | 2009-02-12 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Verbesserung der immunantwort als anwendung in impfstoff und gentherapie |
| KR20070118315A (ko) * | 1999-04-21 | 2007-12-14 | 와이어쓰 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물 |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| AU2003249059A1 (en) * | 2002-07-24 | 2004-02-09 | Arizona Board Of Regents | Use of vaccinia virus deleted for the e3l gene as a vaccine vector |
| US20050281782A1 (en) * | 2004-06-21 | 2005-12-22 | Howard Kaufman | Novel recombinant poxvirus composition and uses thereof |
| US7998733B2 (en) * | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| EP2316942B1 (en) * | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| EP2042604A1 (en) * | 2007-09-26 | 2009-04-01 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | VV promoter driven overexpression of recombinant antigens |
| CA2786333C (en) | 2010-01-28 | 2018-03-20 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of mva |
-
2014
- 2014-11-25 UA UAA201606912A patent/UA127337C2/uk unknown
- 2014-11-25 MX MX2016006758A patent/MX377258B/es active IP Right Grant
- 2014-11-25 HU HUE14806215A patent/HUE056105T2/hu unknown
- 2014-11-25 MY MYPI2016701914A patent/MY188100A/en unknown
- 2014-11-25 PT PT148062151T patent/PT3074517T/pt unknown
- 2014-11-25 CN CN201480062145.2A patent/CN105829537B/zh active Active
- 2014-11-25 US US15/039,777 patent/US20160376596A1/en not_active Abandoned
- 2014-11-25 NZ NZ719934A patent/NZ719934A/en unknown
- 2014-11-25 EP EP21190638.3A patent/EP3971298A3/en active Pending
- 2014-11-25 DK DK14806215.1T patent/DK3074517T3/da active
- 2014-11-25 KR KR1020167013453A patent/KR102504316B1/ko active Active
- 2014-11-25 SI SI201431894T patent/SI3074517T1/sl unknown
- 2014-11-25 NZ NZ759538A patent/NZ759538A/en unknown
- 2014-11-25 WO PCT/EP2014/075522 patent/WO2015078856A1/en not_active Ceased
- 2014-11-25 JP JP2016534624A patent/JP6641276B2/ja active Active
- 2014-11-25 AU AU2014356546A patent/AU2014356546A1/en not_active Abandoned
- 2014-11-25 LT LTEPPCT/EP2014/075522T patent/LT3074517T/lt unknown
- 2014-11-25 ES ES14806215T patent/ES2895977T3/es active Active
- 2014-11-25 BR BR112016011866A patent/BR112016011866A2/pt not_active Application Discontinuation
- 2014-11-25 EP EP14806215.1A patent/EP3074517B1/en active Active
- 2014-11-25 EA EA201691120A patent/EA039037B1/ru unknown
-
2016
- 2016-05-05 IL IL245509A patent/IL245509B/en active IP Right Grant
- 2016-05-11 ZA ZA2016/03187A patent/ZA201603187B/en unknown
-
2019
- 2019-12-26 JP JP2019235645A patent/JP7050044B2/ja active Active
-
2020
- 2020-04-11 US US16/846,325 patent/US20200325477A1/en active Pending
-
2021
- 2021-02-15 AU AU2021200985A patent/AU2021200985B2/en active Active
- 2021-11-08 CY CY20211100963T patent/CY1124707T1/el unknown
-
2024
- 2024-04-30 AU AU2024202790A patent/AU2024202790A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ719934A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| MX2025003310A (es) | Integracion dirigida de acidos nucleicos | |
| MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
| MX2018007860A (es) | Vacunas recombinantes contra el zika. | |
| MX377804B (es) | Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc). | |
| NZ630869A (en) | Compositions and methods for dengue virus chimeric constructs in vaccines | |
| CN106715699A8 (zh) | 用于减弱抗病毒转移载体免疫应答的方法和组合物 | |
| EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
| MX384422B (es) | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras | |
| EP4043031A3 (en) | Zika viral antigen constructs | |
| MX394708B (es) | Composiciones y metodos que usan capsides resistentes a hidrolasas. | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| MX355501B (es) | Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria. | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
| EA201991702A1 (ru) | Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты | |
| PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
| MX391049B (es) | Nuevos promotores | |
| MX2018014253A (es) | Inmunógenos de malaria sintéticos, combinaciones de estos y su uso para prevenir y tratar infecciones de malaria. | |
| MY188494A (en) | High-growth enterovirus 71 strains and vaccines | |
| BR112017003908A2 (pt) | Vacina contra filovírus de vírus de vaccinia modificado recombinante ankara (mva)? | |
| MY185444A (en) | Enterovirus 71 antiviral peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2024 BY CPA GLOBAL Effective date: 20231012 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20251010 |